Company intelligence / Profile preview

Xie Tuo Zhi-M

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

Xietuo Zhi-M is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of next-generation multi-specific antibody therapeutics for oncology. The company utilizes its proprietary M-Body platform to engineer antibodies with enhanced binding affinity and therapeutic efficacy, focusing on immune checkpoint inhibitors and combination therapies. Its lead programs include bispecific antibodies targeting PD-1 and CTLA-4, designed to overcome resistance in various solid tumors. Xietuo Zhi-M aims to provide innovative and affordable biological medicines to patients globally through its integrated R&D and manufacturing capabilities.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyBiologicBispecific monoclonal antibody
Industry: Biotech

Beyond the preview

Go deeper on Xie Tuo Zhi-M.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xie Tuo Zhi-M.

Explore the full profile